Abstract
The results of studies on mice indicate that the antinociceptive effects of kappa-opioid agonists are due, in part, to activation of the 5-HT 2 type of serotonin receptor. One objective of this study was to determine if the discriminative effects of spiradoline, a kappa-opioid agonist, are mediated by 5-HT 2 receptors in rats also. A second objective was to confirm findings that dopamine receptor antagonists produce spiradoline-like discriminative effects (Ohno et al., 1992). Rats were trained to discriminate between spiradoline 3.0 mg/kg) and saline in a discrete-trial avoidance/escape procedure. In subsequent tests of stimulus generalization, the discriminative effects of spiradoline were not mimicked by fenfluramine (0.3–10 mg/kg) or fluoxetine (1.0–10 mg/kg), drugs that enhance serotonergically mediated neurotransmission, nor were they blocked by the 5-HT 2 antagonists pirenperone (0.01–1.0 mg/kg) and ketanserin (0.1–10 mg/kg), or potentiated by fluoxetine pretreatment. Neither the dopamine receptor antagonists haloperidol (0.01–0.3 mg/kg) and sulpiride (3.0–100 mg/kg) nor the agonists apomorphine (0.03–0.3 mg/kg) and d-amphetamine (0.1–3.0 mg/kg) engendered spiradoline-like discriminative effects. These results demonstrate further the pharmacological specificity of the discriminative effects of spiradoline, but provide no evidence for mediation by serotonergic or dopaminergic systems.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have